arrow
P

Paul Lorigan

University of Manchester
H指数:87
被引数:6.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Seasonal variations in overall survival and vitamin D status in a UK pan-cancer cohort receiving checkpoint inhibitors

英国泛癌种队列接受免疫检查点抑制剂治疗患者的总体生存率及维生素D状态的季节性变化

2026-09-290
OAAI
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

原发性黑色素瘤假阴性诊断患者的生命损失年数。一项涉及9063例患者、为期28年的德国中央恶性黑色素瘤登记研究的回顾性研究

2026-07-020
OAAI
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): a randomized open-label phase 2 study

端粒酶疫苗UV1与伊匹木单抗和纳武利尤单抗联用对比伊匹木单抗和纳武利尤单抗治疗晚期黑色素瘤(INITIUM):一项随机开放标签II期研究

2025-12-030
PRE
A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021

2016年至2021年英格兰国家队列研究中黑色素瘤BRAF状态、检测模式、患者及肿瘤特征、治疗与生存情况

2025-10-011
OAAI
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology

关于欧洲转移性黑色素瘤新型治疗方法可及性的最新进展——2024年欧洲黑色素瘤登记系统与欧洲皮肤肿瘤学会联合调查

2025-02-011
PRE
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

皮肤黑色素瘤:ESMO 临床实践指南(用于诊断、治疗和随访)

2025-01-0111
PRE
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

EORTC1325/KEYNOTE-054试验中pembrolizumab与安慰剂在III期黑色素瘤中的七年分析

2024-11-012
PRE
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

单独Anti-PD-1或联合anti-CTLA-4治疗晚期黑色素瘤肝转移患者

2024-07-011
PRE
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after de fi nitive surgery: a multicenter, retrospective cohort study (vol 65, 102290, 2023)

Dabrafenib联合曲美替尼与anti-PD-1单药治疗BRAF V600-mutant III期黑色素瘤术后的辅助治疗: 一项多中心,回顾性队列研究 (第65卷,102290,2023)

2024-05-010
OAAI
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma

MEK抑制剂selumetinib单独或与紫杉醇联合治疗转移性葡萄膜黑色素瘤的三臂随机II期研究

2024-05-012
OAAI